Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals and patients are asked to report any suspected adverse reactions via the national reporting schemes: www.famhp.be/en/side_effect (Belgium) or https://guichet.public.lu/en/entreprises/sectoriel/sante/medecins/notification-effets-indesirables-medicaments.html (Grand Duchy of Luxembourg).
Adverse reactions may also be reported directly to the manufacturer of the suspected product. Adverse reactions related to Gilead products may be reported directly to Gilead via email: [email protected].